Epi-C offers standardised and custom epigenetic assays for
HDAC1, HDAC4, HDAC6, SIRT1, P300 and JMJ.
ISIDE 11 is a new compound for prevention of genetic-based MTHFR-C677T mutation in CVD combined with a cardioprotective rule mediated by SIRT1 activation.
- No cytotoxic effect
- Reduction endothelial dysfunction
- Reduction of thrombogenic trait in MTHFR +/- mutation cases
The present invention relates to a method for the diagnostic of low overall survival acute promyelocytic leukemia and/or of predicting and/or monitoring the response and/or the efficacy of a therapy for acute promyelocytic leukemia or to identify a subject to be treated with an inhibitor of HAT and/or an inhibitor of EZH2 comprising determining the acetylation or methylation status of specific relevant regions and relative kit and microarray. The invention also refers to histone acetyl transferase (HAT) inhibitor for use in the treatment of a solid or liquid tumor.
Fig 1: Schematic depiction of the experimental setup and analysis workflow fo APLs.
The present invention refers to useful SIC2 and SCIC2.1, new compounds as SIRT1 activators, in the prevention and/or treatment of cardiovascular and metabolic disease.
- No cytotoxicity
- SIRT1- mediated effects in genotoxic response
- Reduction of cell senescence
The present invention relates to a method and a device of detecting and measuring Polycyclic Aromatic Hydrocarbons (PAHs)
- Suitable for water, air, biological liquids